Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited naming Micheál Martin .
Filed returns
4
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Novartis Ireland Limited | Health | Valuing Innovation & Advanced Cancer Therapy - policy and access (Public policy or programme) | 27 | On lobbying.ie |
| Sep–Dec 2025 | Novartis Ireland Limited | Health | American Chamber of Commerce Event (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Novartis Ireland Limited | Health | Reimbursement decision for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2017 | Novartis Ireland Limited | Health | Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) | 23 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 4 | 100.0% |